Aaron Carman, PhD is the Program Manager for Aging and Alzheimer’s Prevention at the Alzheimer’s Drug Discovery Foundation. The mission of this program, started in March of 2012, is to provide a credible scientific voice to the general public, medical, and scientific communities in the evaluation and assessment of potential therapies to prevent and delay cognitive aging, Alzheimer’s disease and related dementias.
Dr. Carman trained as a postdoctoral fellow at Memorial Sloan-Kettering Cancer Center where he studied novel small-molecule therapeutics for tau-based neurodegeneration. His earlier postdoctoral training at Cornell University with Margaret Bynoe focused on manipulating blood-brain barrier permeability through adenosine receptor signaling as a novel CNS drug-delivery system. Dr. Carman earned his doctorate in Microbiology and Molecular Genetics with Michael Lorenz at University of Texas Health Science Center in Houston where he studied alternate carbon metabolism in the human fungal pathogen Candida albicans. He earned his BS in Microbiology from Kansas State University. Dr. Carman has authored numerous peer-reviewed publications and is a member of the New York Academy of Sciences, Society for Neuroscience and the Gerontological Society of America.